Vaccine Formulation and Adjuvants are crucial components in the development of effective vaccines, enhancing their immunogenicity and efficacy. Vaccine formulation refers to the precise composition and preparation of vaccines, including the selection of antigens, adjuvants, stabilizers, and delivery systems. The primary goal of vaccine formulation is to stimulate a robust and long-lasting immune response against specific pathogens while ensuring safety and stability. This involves identifying and selecting antigens that are capable of eliciting an immune response and formulating them in a manner that enhances their stability and immunogenicity.
Adjuvants are substances added to vaccines to enhance the immune response to antigens. They work by activating and modulating the innate immune system, increasing antigen presentation and promoting the production of antibodies and memory cells. Common adjuvants include aluminum salts, oil-in-water emulsions, and saponins. The selection of adjuvants depends on various factors, including the type of antigen, the desired immune response, and safety considerations. Adjuvants can improve vaccine efficacy by reducing the amount of antigen required per dose, allowing for dose sparing and increasing the duration and magnitude of the immune response.
In addition to adjuvants, vaccine formulation may also include stabilizers, preservatives, and excipients to enhance vaccine stability, shelf-life, and safety. Stabilizers help protect vaccines from degradation during storage and transport, while preservatives prevent microbial growth and contamination. Excipients such as buffers and pH adjusters maintain the pH and osmolarity of the vaccine formulation, ensuring compatibility with the body's tissues.
Title : Tubercular disease in children: Optimizing treatment strategies through disease insights
Elena Chiappini, University of Florence, Italy
Title : Prophylactic and Molecular Approaches for Mitigating Human Influenza A Viruses: i. Evaluating influenza Vaccine Effectiveness in the Older population ii. Down-regulation of influenza virus genes with novel siRNA-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : Development of a Novel Multi-component Vaccine to Address the Burden of Otitis Media in High-Risk Populations
Ayesha Zahid, Griffith University, Australia
Title : Targeting resistance: New 4-substituted pyrazolidine and isoxazolidine as antibiotics with interesting antimicrobial activities
Yousfi Tarek, Nationale Research for Biotechnology Research Center, Algeria
Title : Racial disparities in pediatric pneumonia in Brazil: The role of structural racism forging inequalities in acess to vaccines
Livia Daflon Silva, Federal University of State of Rio de Janeiro, Brazil
Title : Immunosuppression in COVID-19 Patients and Emerging Fungal Infections: Vaccines, Diagnosis and Strategies to Treat Comorbidities
K R Aneja, Kurukshetra University, India
Title : Immunogenicity and Cryo-EM structure of native-like HIV-1 Clade-C envelope trimers derived from a pediatric elite-neutralizer
Swarandeep Singh, All India Institute of Medical Sciences, India
Title : Why is the vaccine life-threatening if people get a fever after a COVID-19 vaccination
Yacob Mathai, Marma Health Centre, India
Title : Barriers to polio eradication in South Asia: A systematic review
Awranoos Ahadi, Bolan Medical College, Pakistan